--- title: "首次公开募股动态：Avalyn Pharma（AVLN）将扩大后的 IPO 定价为 18 美元——顶级——股票大涨" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/284818412.md" description: "Avalyn Pharma (AVLN) 将其增发的 1667 万股 IPO 定价为 18.00 美元，筹集了 3.0006 亿美元。该股票在纳斯达克首日交易中飙升至 26.00 美元，涨幅达到 44.44%。该公司专注于稀有呼吸系统疾病的吸入治疗，主要候选药物 AP01 和 AP02 正在进行临床试验。尽管 IPO 成功，Avalyn 仍报告了 8520 万美元的净亏损，且去年没有收入" datetime: "2026-04-30T17:05:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284818412.md) - [en](https://longbridge.com/en/news/284818412.md) - [zh-HK](https://longbridge.com/zh-HK/news/284818412.md) --- # 首次公开募股动态：Avalyn Pharma（AVLN）将扩大后的 IPO 定价为 18 美元——顶级——股票大涨 **Avalyn Pharma (AVLN**), **a clinical biotech pioneering inhaled treatments for rare respiratory disorders, priced its upsized IPO of 16.67 million shares at** **$18.00 – the top of its $16.00-to-$18.00 price range – and raised $300.06 million on Wednesday night, April 29, 2026. Shares of Avalyn Pharma (AVLN**) **surged in their NASDAQ debut to open at $26.00 – up $8.00 from the IPO price for a 44.44 percent gain – at 12:23 p.m. EDT today – Thursday, April 30, 2026 – on volume of 813,133 shares. Avalyn Pharma’s stock kept climbing – trading at $27.45 at 12:54 p.m. EDT.** **Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities acted as the joint book-runners on Avalyn’s IPO.** **Avalyn Pharma, focused on pulmonary fibrosis, increased its IPO’s size yesterday to 16.67 million shares – up from 11.8 million shares originally – to raise $283.39 million, if priced at the $17.00 mid-point of its range.** **Avalyn Pharma (AVLN), based in Boston, is focused on developing inhaled treatments for progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF).** **In the prospectus, Avalyn Pharma (AVLN) said its leading drug candidate, AP01 , is an inhaled formulation of pirfenidone to treat progressive pulmonary fibrosis (PPF), and its other leading drug candidate, AP02, is an inhaled formulation of nintedanib to treat idiopathic pulmonary fibrosis, or IPF.** **AP01 is currently being evaluated in MIST, a global Phase 2b clinical trial for the treatment of PPF, according to the prospectus.** **AP02 is currently being evaluated in AURA, a global Phase 2 clinical trial for the treatment of IPF.** **“We are also advancing AP03 into a Phase 1 clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit,” Avalyn Therapeutics said in the prospectus.** **Avalyn Pharma (AVLN) is not profitable: The company reported a net loss of $85.2 million on no revenue for the 12 months that ended Dec. 31, 2025, according to financial statements in the prospectus.** **(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)** **Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.** **To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.** **Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.** ### 相关股票 - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [TMED.US](https://longbridge.com/zh-CN/quote/TMED.US.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [MS.US](https://longbridge.com/zh-CN/quote/MS.US.md) - [JEF.US](https://longbridge.com/zh-CN/quote/JEF.US.md) - [EVR.US](https://longbridge.com/zh-CN/quote/EVR.US.md) - [NDAQ.US](https://longbridge.com/zh-CN/quote/NDAQ.US.md) - [MS-O.US](https://longbridge.com/zh-CN/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/zh-CN/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/zh-CN/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/zh-CN/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/zh-CN/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/zh-CN/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/zh-CN/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/zh-CN/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/zh-CN/quote/MS-K.US.md) ## 相关资讯与研究 - [瑞银上调爵士制药评级：核心业务韧性强劲，新药 Ziihera 成增长引擎](https://longbridge.com/zh-CN/news/286920691.md) - [金融产业日报 (05.20) : 全球债市抛售](https://longbridge.com/zh-CN/news/287110082.md) - [强生重症肌无力治疗新药获国家药监局批准上市](https://longbridge.com/zh-CN/news/287196062.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [Scholar Rock 将出席杰富瑞全球医疗保健大会，聚焦 SMA 新药 apitegromab 关键审批](https://longbridge.com/zh-CN/news/287069556.md)